Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Dapirolizumab Cuts Disease Activity, Steroid Use in SLE
WASHINGTON — The investigational anti-CD40 ligand agent dapirolizumab pegol (DZP) outperformed placebo in improving disease activity and reducing high-dose corticosteroid use in patients with systemic lupus erythematosus (SLE) in the phase 3 PHOENYCS GO trial. “We really think that dapirolizumab…
English